Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vera Therapeutics, Inc. - Class A Common Stock (NQ:VERA)

20.80 -0.79 (-3.66%)
Streaming Delayed Price Updated: 1:57 PM EDT, Apr 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 223,270
Open 21.55
Bid (Size) 20.75 (1)
Ask (Size) 20.83 (2)
Prev. Close 21.59
Today's Range 20.70 - 21.55
52wk Range 18.53 - 51.61
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch
Vera Therapeutics completes enrollment in Phase 3 atacicept trial for IgAN, with interim efficacy results expected this quarter to support 2025 FDA filing. 
Via Benzinga
Exposures Product Safety

Performance

YTD
-50.7%
-50.7%
1 Month
-25.9%
-25.9%
3 Month
-39.9%
-39.9%
6 Month
-48.3%
-48.3%
1 Year
-55.3%
-55.3%

More News

Read More
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
From Vera Therapeutics
Via GlobeNewswire
What's Going On With Vera Therapeutics Stock?
Via Benzinga
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Top 3 Health Care Stocks That Could Blast Off This Quarter
Via Benzinga
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Participate at Upcoming Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years
Via Benzinga
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
Vera Therapeutics Eyes Breakout On Promising Results For Kidney Drug
Via Investor's Business Daily

Frequently Asked Questions

Is Vera Therapeutics, Inc. - Class A Common Stock publicly traded?
Yes, Vera Therapeutics, Inc. - Class A Common Stock is publicly traded.
What exchange does Vera Therapeutics, Inc. - Class A Common Stock trade on?
Vera Therapeutics, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vera Therapeutics, Inc. - Class A Common Stock?
The ticker symbol for Vera Therapeutics, Inc. - Class A Common Stock is VERA on the Nasdaq Stock Market
What is the current price of Vera Therapeutics, Inc. - Class A Common Stock?
The current price of Vera Therapeutics, Inc. - Class A Common Stock is 20.80
When was Vera Therapeutics, Inc. - Class A Common Stock last traded?
The last trade of Vera Therapeutics, Inc. - Class A Common Stock was at 04/16/25 01:57 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.